Canadian firm Neuromed Pharmaceuticals has concluded a special protocol assessment with the FDA for a Phase III clinical trial of its chronic pain treatment. The SPA is part of Neuromed's strategy to release its candidate, known as NMED-1077, in U.S. market by 2009 for people with conditions that result in acute, chronic pain.

Related Summaries